Data from the luciferase assay showed that ZBTB16 suppressed the promoter activity of BCL6 and enhanced that of ZBTB28 (Fig. 6b, c), indicating that ZBTB16 might play an anti-tumor role in breast cancer through regulating ZBTB28 and BCL6. Here, BCL6 is linked to breast carcinoma.